Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Post by nopooon Aug 28, 2013 9:46am
208 Views
Post# 21703062

NIOGOLD MINING RETAINS 100% OF THE MARBAN BLOCK PROPERTY

NIOGOLD MINING RETAINS 100% OF THE MARBAN BLOCK PROPERTYNiogold Mining Corp. has retained its 100-per-cent interest in the Marban block property, following notice that Aurizon Mines Ltd. will not proceed with the third year financing of the option agreement between NioGold and Aurizon.


The option agreement with Niogold would have required Aurizon to fund a further exploration budget of $8,400,000, followed by a resource payment based on the determined number of gold ounces discovered on the property, in order to complete Aurizon's earn in of a 50% interest.
"We are extremely pleased to again have full control and ownership of the Marban property, Niogold's President and CEO Mike Iverson stated. "Aurizon had previously incurred a total of $11,600,000 of exploration expenditures under the option agreement, which has grown the estimated measured and indicated gold resources by 255% to 1.53 million oz (32.1 million tonnes at 1.48 g/t) and the inferred gold resources by 165% to 599,000 oz (16.5 million tonnes at 1.13 g/t)."


"Preliminary metallurgical testing on the Marban deposit was very encouraging. We believe the project has good potential to deliver attractive economics and significant gold production from a combination of open pit and underground development," continued Mr. Iverson. "The Marban Block Property is centrally located in the active Malartic/Val-d'Or gold camps, which has established infrastructure, suppliers and personnel. We look forward to continuing development of the Marban Block Property, targeting the Marban, Norlartic and Kierens deposits, testing new prospective targets, and advancing the economic studies."

<< Previous
Bullboard Posts
Next >>